Leading medical technology company IsoRay (NYSE: ISR) recently launched a new study to analyze the impact and safety of Cesium-131 brachytherapy seeds on recurrent neck and head cancer. The pilot study will be conducted at the Cleveland, Ohio, Case Western Reserve University’s Case Comprehensive Cancer Center, and it will begin enrollment of 42 subjects in early 2017. It is estimated that there are approximately 61,760 cases of neck and head cancer currently diagnosed in the United States. In case of recurrence, which happens with 30-40% of the cases, radiation therapy might not always be possible given the presence of vital anatomy in the neck and head. Cesium-131 brachytherapy seeds, currently used to treat several types of cancer, can be a viable alternative, delivering a compact and conformal radiation dose.
To learn more, visit www.isoray.com
About IsoRay, Inc.
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. This medical technology company is an innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers.
About NetworkNewsBreak
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com.
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
